BiotechTube

AZD1940 + Midazolam

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Low Back Pain

Conditions

Low Back Pain

Trial Timeline

Mar 1, 2008 → Nov 1, 2008

NCT ID
NCT00689780

About AZD1940 + Midazolam

AZD1940 + Midazolam is a phase 1 stage product being developed by AstraZeneca for Low Back Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00689780. Target conditions include Low Back Pain.

What happened to similar drugs?

9 of 20 similar drugs in Low Back Pain were approved

Approved (9) Terminated (3) Active (11)
✅tramadol hydrochloride , acetaminophenJohnson & JohnsonApproved
✅Diclofenac + CelecoxibPfizerApproved
✅PregabalinPfizerApproved
✅valdecoxib + diclofenacPfizerApproved
✅pregabalin and celecoxib + Placebo and celecoxibPfizerApproved
✅Tramadol Hydrochloride 50mg + Celebrex 200mgPfizerApproved
✅FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%PfizerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00689780Phase 1Completed

Competing Products

20 competing products in Low Back Pain

See all competitors
ProductCompanyStageHype Score
LY3556050 + PlaceboEli LillyPhase 2
35
LY3526318 + PlaceboEli LillyPhase 2
35
DuloxetineShionogiPhase 3
40
Duloxetine + PlaceboShionogiPhase 3
40
Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
40
EperisoneEisaiPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY3857210 + PlaceboEli LillyPhase 2
35
LY3016859 + PlaceboEli LillyPhase 2
35
Duloxetine + PlaceboEli LillyPhase 3
40
Placebo to Week 16; tanezumab 5mg SC + Placebo to Week 16, tanezumab 10 mg SC + Tanezumab 5 mg SC + Tanezumab 10 mg SC + Tramadol PR oralEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
JNJ-42160443 3 mg + JNJ-42160443 1 mg + JNJ-42160443 6 mg/3mg + JNJ-42160443 10 mg + Matching PlaceboJohnson & JohnsonPhase 2
27
tramadol hydrochloride , acetaminophenJohnson & JohnsonApproved
35
tapentadol (CG5503) Immediate Release IR + tapentadol (CG5503) Extended Release (ER) + tapentadol (CG5503) Immediate Release (IR)Johnson & JohnsonPhase 3
40
tapentadol (CG5503) ER + oxycodone CR + placeboJohnson & JohnsonPhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
hydrocodone/acetaminophen extended release + PlaceboAbbViePhase 2
35
MK-0663B + DOLOCAM PLUS® + Acetaminophen 500 mgMerckPhase 3
32